Lifestyle interventions in patients after colorectal cancer treatment

A recent RCT reveals the HEAL ABC intervention is feasible for 87% of colorectal cancer survivors, supporting healthy lifestyle changes and improved well-being.

FDA Approves Blood Test for Colon Cancer Screening

The FDA approved the Shield blood test for colorectal cancer (CRC) screening in adults ages 45 and older at average risk for the disease, Guardant

July 30, 2024

Risk Adjusted Net Present Value: What is the current valuation of PMV Pharmaceuticals’s Rezatapopt

The revenue for Rezatapopt is expected to reach an annual total of $63 mn by 2040 globally based off GlobalData’s Revenue Model. The drug’s revenue

July 2, 2024

Affluent Medical signs agreements for mitral valve technologies with EUR 15M upfront payment – Biotech Investments

EQS-News: Affluent Medical SA / Key word(s): Agreement Affluent Medical signs agreements for mitral valve technologies with EUR 15M upfront payment 12.07.2024 / 07:45 CET/CEST

July 13, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.